RESEARCH



Efficacy and safety of duloxetine in chronic musculoskeletal pain: a systematic review and meta-analysis

Xuezhi Ma^{1,2†}, Shijie Zhou^{1,2†}, Wenyuan Sun^{1,2}, Jie Sun², Guangguang Li³, Lining Wang^{2,4,5*} and Yang Guo^{2*}

Abstract

Background Chronic musculoskeletal pain (CMP) is a complex condition that is mainly treated with analgesic drugs. However, antidepressant intervention is also an important factor in the treatment of CMP. Duloxetine is an effective treatment option for patients with CMP as its antidepressant effect. The purpose of this article is to evaluate the efficacy and safety of duloxetine in treating CMP.

Databases and data treatment We searched PubMed, Web of Science, Embase, Cochrane Library from inception to May, 2022. Randomized controlled trials (RCTs) evaluating the efficacy and safety of duloxetine versus placebo in patients with CMP were included. We identified 13 articles and studied a population of 4201 participants in 4 countries.

Results This meta-analysis showed that the duloxetine has statistically significant compared with the placebo control, benefits on 24-hour average pain, living quality, physical function, and global impressions and there was no difference in the incidence of serious adverse event. In general, duloxetine can improve mood and pain level at the same time.

Conclusions This review shows a significant contribution of duloxetine to CMP symptom relief. This meta-analysis improved that duloxetine can significantly reduce the pain level of patients, improve depressive symptoms and global impression, and has no obvious serious adverse reactions. However, additional studies are required to confirm the relationship between psychological diseases and chronic pain and explore their internal links.

Keywords Duloxetine, Chronic musculoskeletal pain, Pain, Meta-analysis

[†]Xuezhi Ma and Shijie Zhou contributed equally to this work.

*Correspondence: Lining Wang wln@njucm.edu.cn Yang Guo drguoyang@njucm.edu.cn ¹Department of Orthopedics, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, China ²Laboratory of New Techniques of Restoration & Reconstruction of Orthopedics and Traumatology, Nanjing University of Chinese Medicine, Nanjing, China ³Yixing Hospital of Traditional Chinese Medicine, Wuxi, Wuxi, China

⁴School of Chinese Medicine, School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China ⁵Chinese Medicine Centre (International Collaboration between Western Sydney University and Beijing University of Chinese Medicine), Western Sydney University, Sydney, Australia



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Chronic musculoskeletal pain (CMP) is a persistent pain that affects muscles, joints, bones and other parts of the human body. CMP encompasses a wide range of motor system diseases, including osteoarthritis, neck pain, low back pain and fibromyalgia syndrome. About 20-33% of the global population suffers from CMP. With the increasing of population aging and social pressure, the incidence of CMP has increased significantly [1]. In addition to pain and dysfunction, CMP can also lead to depression and psychological disorders in patients. About 43.3% of patients with CMP had depression or bipolar disorder [2]. According to a meta-analysis [3], individuals who experience chronic pain report higher depression than those healthy controls. Long-term chronic pain and psychological disorders greatly reduce patients' quality of life while imposing a significant psychological and economic burden on patients and their families.

Currently, treatment of CMP relies on analgesic drugs such as non-steroidal anti-inflammatory drugs (NSAIDs), antipyretics, opioids, and muscle relaxants. However, NSAIDs will increase the risk of peptic ulcer, gastrointestinal bleeding, cardiovascular adverse events and have poor efficacy [4–6]. Antipyretics such as acetaminophen also have a risk of acute liver failure [7, 8]. Opioids have strong analgesic effects but are prone to serious adverse reactions such as dependence, abuse and addiction [9]. For patients with CMP and psychological disorders, analgesic drugs have limited therapeutic effects. Therefore, finding a relatively safe and effective drug is an urgent problem in the process of making CMP medical decisions.

Duloxetine, a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI), is the only antidepressant drug approved by Food and Drug Administration (FDA) to treat CMP [10]. Duloxetine can resist depression, anxiety and adverse psychological emotion, and it can also inhibit the release of excitatory neurotransmitters, blunt the nociceptive pathway, and play a comprehensive effect on CMP. Duloxetine has a good safety profile and a low dose for long-term use in patients with chronic pain of different races in a retrospective analysis [11]. There have been meta-analyses on the efficacy and safety of duloxetine for knee osteoarthritis or chronic low back pain [12, 13], but few studies were included. This study conducted a meta-analysis on the efficacy and safety of duloxetine in the treatment of patients with CMP by expanding the sample size and types of diseases. We try to provide relevant basis for the necessity of antidepressant treatment in the treatment of CMP by studying the effect of duloxetine on the mood and psychological state of patients with CMP.

Methods

Literature search

We searched PubMed, Cochrane Library, Medline, Web of Science from inception to May, 2022 by using a combination of abstract and key words, such as "duloxetine", "chronic musculoskeletal pain", "osteoarthritis", "fibromyalgia". We limited the literature what was published but did not place any limits on language or publication date.

Inclusion criteria and exclusion criteria

The title and abstract were obtained by two independent researchers, and we used EndNote to manage the retrieved literature. After reading the title, abstract and full text, the literature was screened and checked. If there was any disagreement, the third researcher would decide. The literature we included had to meet the following criteria: (1) study type: RCTs of efficacy and safety of duloxetine in the treatment of CMP, such as knee osteoarthritis (KOA) or fibromyalgia; (2) study group: Patients diagnosed as KOA or fibromyalgia and the course of disease was more than 3 months; (3) interventions: Duloxetine was used in the test group, placebo was used in the control group, and NSAIDs were allowed to be used together; (4) the outcome indicators included at least one of the following: Brief Pain Inventory-Severity(BPI-S), Brief Pain Inventory-Interference(BPI-I), Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC)、36-Item Short-Form Health Status Survey(SF-36), Clinical Global Impressions of Severity(CGI-S), Patients' Global Impression of Improvement(PGI-I), Serious Adverse Events(SAEs), and data were extracted at the end of follow-up for each outcome.

Data extraction

Two researchers (Xuezhi Ma, Shijie Zhou) screened and extracted the data independently, reviewing the title, abstract, and full text of each article, and consulted a third researcher (Yang Guo) when disputations arose. The extracted data mainly includes the following contents: (1) basic information of each study including first author, country, publication year, study design, etc.; (2) age of patients, sample size, interventions, period of treatment; (3) the data of case and control groups; (4) potential sources of biases.

Quality assessment

We assessed the risk of bias for each study using the items in Cochrane Collaboration's tool [14] for assessing quality in randomized trials, which included the following items: (1) selection bias included random sequence generation and allocation concealment; (2) blinding of participants, personnel, and outcome assessment; (3) incomplete outcome data; (4) selective reporting; (5)

other potential bias. We evaluated all the above biases and divided them into "low, unclear and high bias risks". On this basis, we used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool to further evaluate the level of the included literature, which is divided into "high, medium, low or very low" quality.

Statistical analysis

In this study, we tried to contact the authors to obtain the original data when the data were missing or incomplete. For data that were not available, the investigators used the evidence-based transformation formula to obtain means and other corresponding data [15]. Pooled mean difference (MD) with 95% confident interval (CI) was calculated for continuous data while relative risk (RR) with 95% CI for dichotomous data. Heterogeneity was assessed using the I² statistic. If I²<50%, the heterogeneity of articles was considered to be small, and the fixed effects model was used. Otherwise, the random-effects

model was used [16]. In addition, sensitivity analysis would also be performed in the case of heterogeneity by eliminating one study at a time, so as to check for the resolution of heterogeneity [17]. Besides, the publication bias was assessed using the visual funnel plot and Egger's test, with a P < 0.05 indicating significant publication bias [18]. Forest plots were used to display the results from individual studies and pooled estimates, and P < 0.05 were regarded as statistically significant. Data analysis was performed using RevMan 5.3.

Results

Study selection

As is briefly illustrated in Fig. 1, 1067 articles were obtained according to the literature retrieval strategy. After deleting the duplicate content and screening the title and abstract, 1043 articles were excluded. 11 articles were excluded due to inappropriate intervention or other reasons. Finally, 13 studies [19–31] from 4 countries met our eligibility.




Fig. 1 PRISMA Flow chart of study selection

Study characteristics

The baseline characteristics and treatment regimens of the 13 eligible studies with a total sample size of 4201 patients are displayed in Table 1. All included studies were compared with placebo, while 6 studies [19, 22–26] were patients with KOA and 7 studies [20, 21, 27-31] were patients with fibromyalgia.

Quality assessment

The quality assessment of the trials was performed using the Cochrane Collaboration's risk-of-bias tool. Two studies [25, 26] explicitly described the stochastic methods, and the rest of the studies [19-24, 27-31] just mentioned "random". None of the studies described detailed allocation concealment processes. Blinding of participants and personnel occurred in all 13 studies. In general, all studies we included had a low risk of bias. The detailed results are presented in Fig. 2.

Meta-analysis results

In the 13 eligible RCTs, 12 trials [19-22, 24-31] measured pain level using BPI-S and 8 trials [19-22, 24-26, 30] assessed living quality by BPI-I. Six trials [19, 22–26] evaluated the physical function using WOMAC physical function and stiffness subscale. Some trials compared the patient's global impression measured by CGI-S [19-22, 24-31] and PGI-I [19, 20, 22, 24-28, 30, 31]. Ten trials

Effect of duloxetine on pain relief

Twelve trials contributed to the meta-analysis of pain relief based on the BPI-S. Compared with the placebo control groups, the meta-analysis results indicated that patients in the duloxetine groups had significant reductions in the average pain within 24 h (12 articles; 3683 patients; MD= -0.74; 95% CI, -0.88 to -0.60; P<0.00001) (Fig. 3A), worst pain (9 articles; 2885 patients; MD= -0.83; 95% CI, -1.01 to -0.65; P<0.00001)(Fig. 3B), least pain (9 articles; 2885 patients; MD= -0.60; 95% CI, -0.75 to -0.44; P<0.00001) (Fig. 3C) and pain right now (9 articles; 2885 patients; MD= -0.70; 95% CI, -0.86 to -0.53; P<0.00001) (Fig. 3D). These studies suggest that duloxetine significantly relief pain in patients with CMP.

Effects of duloxetine in the interference of pain and quality of life


Eight trials contributed to the meta-analysis of the interference of pain and quality of life based on the BPI-I. The meta-analysis results revealed that the duloxetine group showed prominent improvement in the interference of pain on general activity (8 articles; 2496 patients; MD= -0.77; 95% CI, -0.95 to -0.59; P<0.00001) (Fig. 4A), mood (7 articles; 2239 patients; MD= -0.61; 95% CI, -0.80 to -0.43; P<0.00001) (Fig. 4B), walking ability (7

 Table 1
 Baseline characteristics and treatment regimen of included studies

Study	Time	Location	Population	Trial	Group		Con	trol Group		Study	Main outcome
				n	Age(y)	Treatment regimen	n	Age(y)	Treatment regimen	dura- tion (wk)	
Himanshu	2019	USA	fibromyalgia	91	15.74+1.4	Duloxetine 30-60 mg/d	93	15.33+1.4	placebo	13	1257
Uchio	2018	Japan	KOA	177	65.5 ± 8.0	Duloxetine 60 mg/d	176	66.4 ± 8.4	placebo	14	1234567
Wang	2017	China	KOA/Hip	205	61.2 ± 8.2	Duloxetine 60 mg/d	202	59.8 ± 8.4	placebo	13	123567
Murakami	2015	Japan	fibromyalgia	191	47.8 ± 12.0	Duloxetine 60 mg/d	195	49.5 ± 11.7	placebo	14	124567
Abou-Raya	2012	Egypt	KOA	144	68.9 ± 6.2	Duloxetine 60 mg/d	144	68.5 ± 5.8	placebo	16	3
Arnold	2012	USA	fibromyalgia	155	50.9 ± 11.9	Duloxetine 30 mg/d	153	50.7 ± 12.5	placebo	12	14567
Frakes	2011	USA	КОА	264	61.6±9.2	Duloxetine 60- 120 mg/d + NSAIDs	260	60.3±9.2	place- bo+NSAIDs	10	123567
Chappell	2011	USA	КОА	128	63.2±8.8	Duloxetine 60-120 mg/d	128	61.9±9.2	placebo	13	1234567
Arnold	2010	USA	fibromyalgia	263	50.7±11.3	Duloxetine 60-120 mg/d	267	49.6+10.8	placebo	24	1457
Chappell	2009	USA	КОА	111	62.1±9.6	Duloxetine 60-120 mg/d	120	62.5±9.3	placebo	13	1234567
Russell	2008	USA	fibromyalgia	147	51.5 ± 10.8	Duloxetine 120 mg/d	144	50.3±10.9	placebo	24	1456
Arnold	2005	USA	fibromyalgia	116	49.6±10.9	Duloxetine 120 mg/d	120	49.6±10.9	placebo	12	124567
Arnold	2004	USA	fibromyalgia	104	49.9±12.3	Duloxetine 120 mg/d	103	48.3±11.3	placebo	12	1456

Main outcome: 1) BPI-S, Brief Pain Inventory-Severity; 2) BPI-I, Brief Pain Inventory-Interference; 3) WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; ④SF-36,36-Item Short-Form Health Status Survey; ⑤CGI-5, Clinical Global Impressions of Severity; ⑥PGI-I, Patient's Global Impression of Improvement; ⑦SAEs, serious adverse events

Abbreviations: KOA, Knee osteoarthritis; NSAIDs, non-steroidal anti-inflammatory drugs






Fig. 2 Risk of bias summary and assessment summary of randomized controlled trials (green = low risk; red = high risk; yellow = unknown)

articles; 2240 patients; MD= -0.71; 95% CI, -0.90 to -0.51; P<0.0001) (Fig. 4C), normal work (8 articles; 2496 patients; MD= -0.70; 95% CI, -0.88 to -0.52; P<0.00001) (Fig. 4D), interpersonal relationship (7 articles; 2239 patients; MD= -0.55; 95% CI, -0.85 to -0.25; P=0.0003) (Fig. 4E), sleep (7 articles; 2240 patients; MD= -0.51; 95% CI, -0.69 to -0.33; P<0.00001) (Fig. 4F), enjoyment of life (7 articles; 2240 patients; MD= -0.64; 95% CI, -0.97 to -0.32; P=0.0001) (Fig. 4G) and average interference (7 articles; 2032 patients; MD= -0.52; 95% CI, -0.68 to -0.36; P<0.00001) (Fig. 4H) than placebo control group, which indicated that duloxetine can improve the interference of pain, depressive symptoms and the quality of life significantly.

		oxetin			acebo	T	Mr. L.I.	Mean Difference	Mean Difference
Study or Subgroup	Mean			Mean			Weight	IV, Fixed, 95% CI	IV. Fixed, 95% Cl
Arnold 2004	-1.83	2.4	100	-0.94		102	4.7%	-0.89 [-1.54, -0.24]	
Arnold 2005		2.35	114	-1.16		118	5.6%	-1.24 [-1.84, -0.64]	· · · · · · · · · · · · · · · · · · ·
Arnold 2010	-2.3	2.74	188	-1.5	2.82	199	6.5%	-0.80 [-1.35, -0.25]	
Arnold 2012	-2.14		153	-1.83		153	6.5%	-0.31 [-0.86, 0.24]	
Chappell 2009	-2.82		107	-1.85		116	5.9%	-0.97 [-1.55, -0.39]	
Chappell 2011	-2.51	2.26	128	-1.72		128	7.2%	-0.79 [-1.32, -0.26]	
Frakes 2011		2.25	258	-1.54	2.72	256	10.7%	-1.02 [-1.45, -0.59]	
Himanshu 2019	-1.62	2.36	91	-0.97		93	4.3%	-0.65 [-1.33, 0.03]	
Murakami 2015	-1.6	3.59	191	-1.22	3.63	195	3.8%	-0.38 [-1.10, 0.34]	
Russell 2008		2.55	147 177		2.52	144 176	5.9%	-0.83 [-1.41, -0.25]	
Uchio 2018 Wang 2017	-2.57			-1.73	1.59	176	17.8% 21.0%	-0.77 [-1.10, -0.44] -0.50 [-0.81, -0.19]	
wang 2017	-2.23	1.40	112	-1.75	1.40	177	21.076	-0.50 [-0.81, -0.19]	
Total (95% CI)			1826			1857	100.0%	-0.74 [-0.88, -0.60]	•
Heterogeneity: Chi ² =	11.00. d	f = 11 f		(4): $ ^2 =$	0%				+ + + +
Test for overall effect:					0.10				-2 -1 0 1
		. (.	010000	,					Favours [Duloxetinel] Favours [placebo]
В	Du	oxetin	1e	PI	acebo			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Fixed, 95% C	IV. Fixed, 95% CI
Arnold 2005	-2.37	2.7	114	-1.35	2.6	118	6.7%	-1.02 [-1.70, -0.34]	
Arnold 2010	-2.5	2.74	188	-1.7	2.82	199	10.1%	-0.80 [-1.35, -0.25]	
Chappell 2009	-3.29	2.42	107	-2.23	2.38	117	7.8%	-1.06 [-1.69, -0.43]	
Chappell 2011	-2.77	2.6	128	-1.95	2.49	128	8.0%	-0.82 [-1.44, -0.20]	
Frakes 2011	-2.71	2.57	258	-1.61	2.56	256	15.8%	-1.10 [-1.54, -0.66]	
Himanshu 2019	-1.43	2.62	91	-0.96	2.57	93	5.5%	-0.47 [-1.22, 0.28]	
Murakami 2015	-1.91	3.59	191	-1.35	3.63	195	6.0%	-0.56 [-1.28, 0.16]	
Uchio 2018	-2.92	1.96	177	-2.13	1.95	176	18.6%	-0.79 [-1.20, -0.38]	
Wang 2017	-2.71	1.79	172	-2	1.82	177	21.6%	-0.71 [-1.09, -0.33]	
Total (95% CI)			1426			1459	100.0%	-0.83 [-1.01, -0.65]	▲ · · ·
Heterogeneity: Chi ² =			= 0.85		%	1459	100.0%	-0.83 [-1.01, -0.65]	
			= 0.85		%	1459	100.0%	-0.83 [-1.01, -0.65]	-2 -1 0 1 Favours [Duloxetine] Favours [placebo]
Heterogeneity: Chi ² =	Z = 9.24	(P < (= 0.85) 0.0000	1)			100.0%		Favours [Duloxetine] Favours [placebo]
Heterogeneity: Chi ² = Test for overall effect: C	Z = 9.24 Dul	(P < (= 0.85) 0.00001	1) Pl	acebo			Mean Difference	Favours [Duloxetine] Favours [placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup	Z = 9.24 Dul Mean	(P < (oxetin SD	= 0.85) 0.00007 ne Total	1) Pl Mean	acebo SD	Total	Weight	Mean Difference IV, Fixed, 95% C	Favours [Duloxetine] Favours [placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005	Z = 9.24 Dul <u>Mean</u> -1.76	(P < (loxetin <u>SD</u> 2.14	= 0.85) 0.00001 ne <u>Total</u> 114	1) PI <u>Mean</u> -0.58	acebo SD 2.17	Total 118	Weight 7.6%	Mean Difference IV, Fixed, 95% C -1.18 [-1.73, -0.63]	Favours [Duloxetine] Favours [placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: <u>Study or Subgroup</u> Arnold 2005 Arnold 2010	Z = 9.24 Dul <u>Mean</u> -1.76 -1.7	(P < 0 loxetin <u>SD</u> 2.14 2.74	= 0.85) 0.00007 ne <u>Total</u> 114 188	1) PI <u>Mean</u> -0.58 -1.1	acebo SD 2.17 2.82	<u>Total</u> 118 199	Weight 7.6% 7.6%	Mean Difference IV, Fixed. 95% Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05]	Favours [Duloxetine] Favours [placebo] Mean Difference
Heterogeneity: Chi ² = - Test for overall effect: Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2009	Z = 9.24 Dul <u>Mean</u> -1.76 -1.7 -2.4	(P < 0 sp 2.14 2.74 2.23	= 0.85) 0.00007 ne <u>Total</u> 114 188 107	1) PI Mean -0.58 -1.1 -1.64	acebo <u>SD</u> 2.17 2.82 2.06	<u>Total</u> 118 199 117	Weight 7.6% 7.6% 7.4%	Mean Difference IV, Fixed. 95% C -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20]	Favours [Duloxetine] Favours [placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2009 Chappell 2011	Z = 9.24 Dul <u>Mean</u> -1.76 -1.7 -2.4 -1.89	(P < 0 SD 2.14 2.74 2.23 2.38	= 0.85) 0.00001 10 <u>Total</u> 114 188 107 128	PI Mean -0.58 -1.1 -1.64 -1.28	acebo <u>SD</u> 2.17 2.82 2.06 2.38	Total 118 199 117 128	Weight 7.6% 7.6% 7.4% 6.9%	Mean Difference IV, Fixed, 95% C -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.61 [-1.19, -0.03]	Favours [Duloxetine] Favours [placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2009 Chappell 2011 Frakes 2011	Z = 9.24 Dul <u>Mean</u> -1.76 -1.7 -2.4 -1.89 -1.95	(P < 0 sp 2.14 2.74 2.23 2.38 2.09	= 0.85 0.0000 ne <u>Total</u> 114 188 107 128 258	PI -0.58 -1.1 -1.64 -1.28 -1.25	acebo <u>SD</u> 2.17 2.82 2.06 2.38 2.08	Total 118 199 117 128 256	Weight 7.6% 7.6% 7.4% 6.9% 18.0%	Mean Difference IV, Fixed, 95% Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.61 [-1.19, -0.03] -0.70 [-1.06, -0.34]	Favours [Duloxetine] Favours [placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2010 Chappell 2011 Frakes 2011 Himanshu 2019	Z = 9.24 Dui <u>Mean</u> -1.76 -1.7 -2.4 -1.89 -1.95 -0.96	P < 0 5D 2.14 2.74 2.23 2.38 2.09 2.36	= 0.85 0.0000 ne <u>Total</u> 114 188 107 128 258 91	PI -0.58 -1.1 -1.64 -1.28 -1.25 -0.6	acebo SD 2.17 2.82 2.06 2.38 2.08 2.33	Total 118 199 117 128 256 93	Weight 7.6% 7.6% 7.4% 6.9% 18.0% 5.1%	Mean Difference IV, Fixed, 95% CI -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.15, -0.03] -0.70 [-1.06, -0.34] -0.36 [-1.04, 0.32]	Favours [Duloxetine] Favours [placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Armold 2010 Chappell 2009 Chappell 2010 Frakes 2011 Himanshu 2019 Murakami 2015	Z = 9.24 Dui <u>Mean</u> -1.76 -1.7 -2.4 -1.89 -1.95 -0.96 -1.72	P < 0 2.14 2.74 2.23 2.38 2.09 2.36 3.04	= 0.85) 0.0000 ⁻ ne <u>Total</u> 114 188 107 128 258 91 191	PI <u>Mean</u> -0.58 -1.1 -1.64 -1.28 -1.25 -0.6 -1.23	acebo SD 2.17 2.82 2.06 2.38 2.08 2.33 3.07	Total 118 199 117 128 256 93 195	Weight 7.6% 7.6% 7.4% 6.9% 18.0% 5.1% 6.3%	Mean Difference IV, Fixed, 95% C -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.61 [-1.19, -0.03] -0.70 [-1.06, -0.34] -0.36 [-1.04, 0.32] -0.48 [-1.10, 0.12]	Favours [Duloxetine] Favours [placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: CULV or Subgroup Arnold 2005 Arnold 2010 Chappell 2010 Chappell 2009 Chappell 2011 Himanshu 2019 Murakami 2015 Uchio 2018	Z = 9.24 Dul <u>Mean</u> -1.76 -1.7 -2.4 -1.89 -1.95 -0.96 -1.72 -1.61	P < 0 2.14 2.74 2.23 2.38 2.09 2.36 3.04 1.42	= 0.85) 0.0000 ne <u>Total</u> 114 188 107 128 258 91 191 177	PI PI -0.58 -1.1 -1.64 -1.28 -1.25 -0.6 -1.23 -1.05	acebo <u>SD</u> 2.17 2.82 2.06 2.38 2.08 2.33 3.07 1.48	Total 118 199 117 128 256 93 195 176	Weight 7.6% 7.6% 7.4% 6.9% 18.0% 5.1% 6.3% 25.6%	Mean Difference IV, Fixed, 95% Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.6, -0.34] -0.36 [-1.04, -0.32] -0.49 [-1.10, -0.12] -0.55 [-0.86, -0.26]	Favours [Duloxetine] Favours [placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Armold 2010 Chappell 2009 Chappell 2010 Frakes 2011 Himanshu 2019 Murakami 2015	Z = 9.24 Dui <u>Mean</u> -1.76 -1.7 -2.4 -1.89 -1.95 -0.96 -1.72	P < 0 2.14 2.74 2.23 2.38 2.09 2.36 3.04 1.42	= 0.85) 0.0000 ⁻ ne <u>Total</u> 114 188 107 128 258 91 191	PI -0.58 -1.1 -1.64 -1.28 -1.25 -0.6 -1.23 -1.05	acebo SD 2.17 2.82 2.06 2.38 2.08 2.33 3.07	Total 118 199 117 128 256 93 195	Weight 7.6% 7.6% 7.4% 6.9% 18.0% 5.1% 6.3% 25.6% 15.4%	Mean Difference IV, Fixed, 95% Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.32, -0.20] -0.70 [-1.06, -0.34] -0.70 [-1.06, -0.34] -0.36 [-1.04, 0.32] -0.49 [-1.10, 0.12] -0.45 [-0.86, -0.26] -0.28 [-0.67, 0.11]	Favours [Duloxetine] Favours [placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: Cutdy or Subgroup Arnold 2005 Arnold 2010 Chappell 2009 Chappell 2009 Chappell 2009 Murakami 2015 Murakami 2019 Murakami 2015 Wang 2017 Total (95% CI)	Z = 9.24 Dul <u>Mean</u> -1.76 -1.7 -2.4 -1.89 -1.95 -0.96 -1.72 -1.61 -1.48	P (P < 0 oxetin <u>SD</u> 2.14 2.74 2.23 2.38 2.09 2.36 3.04 1.42 2.07	= 0.85; 0.0000 ne <u>Total</u> 114 188 107 128 258 91 191 177 172 1426	PI Mean -0.58 -1.1 -1.64 -1.28 -1.25 -0.6 -1.23 -1.05 -1.2	2.17 2.82 2.06 2.38 2.08 2.33 3.07 1.48 1.62	Total 118 199 117 128 256 93 195 176	Weight 7.6% 7.6% 7.4% 6.9% 18.0% 5.1% 6.3% 25.6% 15.4%	Mean Difference IV, Fixed, 95% Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.6, -0.34] -0.36 [-1.04, -0.32] -0.49 [-1.10, -0.12] -0.55 [-0.86, -0.26]	Favours [Duloxetine] Favours [placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2009 Chappell 2010 Frakes 2011 Himanshu 2019 Murakami 2015 Uchio 2018 Wang 2017	Z = 9.24 Dul <u>Mean</u> -1.76 -1.7 -2.4 -1.89 -1.95 -0.96 -1.72 -1.61 -1.48	P (P < 0 oxetin <u>SD</u> 2.14 2.74 2.23 2.38 2.09 2.36 3.04 1.42 2.07	= 0.85; 0.0000 ne 114 188 107 128 258 91 191 177 172 1426	PI Mean -0.58 -1.1 -1.64 -1.28 -1.25 -0.6 -1.23 -1.05 -1.2	2.17 2.82 2.06 2.38 2.08 2.33 3.07 1.48 1.62	Total 118 199 117 128 256 93 195 176 177	Weight 7.6% 7.6% 7.4% 6.9% 18.0% 5.1% 6.3% 25.6% 15.4%	Mean Difference IV, Fixed, 95% Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.32, -0.20] -0.70 [-1.06, -0.34] -0.70 [-1.06, -0.34] -0.36 [-1.04, 0.32] -0.49 [-1.10, 0.12] -0.45 [-0.86, -0.26] -0.28 [-0.67, 0.11]	Favours [Duloxetine] Favours [placebo] Mean Difference IV, Fixed, 95% Cl
Heterogeneity: Chi ² = Test for overall effect: Cutdy or Subgroup Arnold 2005 Arnold 2010 Chappell 2009 Chappell 2009 Chappell 2009 Murakami 2015 Murakami 2019 Murakami 2015 Wang 2017 Total (95% CI)	Z = 9.24 <u>Mean</u> -1.76 -1.77 -2.4 -1.89 -1.95 -0.96 -1.72 -1.61 -1.48 8.06, df	P (P < 0 2.14 2.74 2.23 2.38 2.09 2.36 3.04 1.42 2.07 = 8 (P	= 0.85 0.0000 ne <u>Total</u> 114 188 107 128 258 91 191 177 172 1426 = 0.43)	PI Mean -0.58 -1.1 -1.64 -1.28 -0.6 -1.23 -1.05 -1.2 (1 ² = 19	2.17 2.82 2.06 2.38 2.08 2.33 3.07 1.48 1.62	Total 118 199 117 128 256 93 195 176 177	Weight 7.6% 7.6% 7.4% 6.9% 18.0% 5.1% 6.3% 25.6% 15.4%	Mean Difference IV, Fixed, 95% Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.32, -0.20] -0.70 [-1.06, -0.34] -0.70 [-1.06, -0.34] -0.36 [-1.04, 0.32] -0.49 [-1.10, 0.12] -0.45 [-0.86, -0.26] -0.28 [-0.67, 0.11]	Favours [Duloxetine] Favours [placebo] Mean Difference IV, Fixed, 95% Cl
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2011 Frakes 2011 Himanshu 2019 Murakami 2015 Uchio 2018 Wang 2017 Total (95% CI) Heterogeneity: Chi ² =	Z = 9.24 Dul <u>Mean</u> -1.76 -1.7 -2.4 -1.89 -1.95 -0.96 -1.72 -1.61 -1.78 8.06, df Z = 7.63	2.14 2.74 2.23 2.38 2.09 2.36 3.04 1.42 2.07 = 8 (P < 0	= 0.85 0.0000 ⁻ 114 188 107 128 258 91 191 177 172 1426 = 0.43 0.0000 ⁻	PI Mean -0.58 -1.1 -1.64 -1.25 -0.6 -1.23 -1.05 -1.2 (1 ² = 19 (1)	acebo <u>SD</u> 2.17 2.82 2.06 2.38 2.08 2.33 3.07 1.48 1.62	Total 118 199 117 128 256 93 195 176 177 1459	Weight 7.6% 7.6% 7.4% 6.9% 18.0% 5.1% 6.3% 25.6% 15.4%	Mean Difference IV. Fixed. 95% Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.32, -0.20] -0.76 [-1.32, -0.20] -0.36 [-1.04, 0.32] -0.36 [-1.04, 0.32] -0.36 [-1.04, 0.32] -0.36 [-0.76, -0.26] -0.28 [-0.67, -0.14]	Favours [Duloxetine] Favours [placebo]
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Amold 2005 Amold 2010 Chappell 2009 Chappell 2009 Chappell 2011 Frakes 2011 Himanshu 2019 Murakami 2015 Uchio 2018 Wang 2017 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect: D	Z = 9.24 <u>Mean</u> -1.76 -1.77 -2.4 -1.89 -1.95 -0.96 -1.72 -1.61 -1.48 8.06, df Z = 7.63 Dul	P (P < 0 boxetin <u>SD</u> 2.14 2.74 2.23 2.38 2.09 2.36 3.04 1.42 2.07 = 8 (P < 0 boxetin	= 0.85 0.0000 Total 114 188 107 128 258 91 191 177 172 1426 = 0.43 0.00001 ne	PI <u>Mean</u> -0.58 -1.1 -1.64 -1.25 -0.6 -1.23 -1.05 -1.2 (1 ² = 19) PI	acebo <u>SD</u> 2.17 2.82 2.06 2.38 2.08 2.33 3.07 1.48 1.62	Total 118 199 117 128 256 93 195 176 177 1459	Weight 7.6% 7.4% 6.9% 18.0% 5.1% 6.3% 25.6% 15.4%	Mean Difference IV, Fixed, 95% CI -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.32, -0.20] -0.76 [-1.06, -0.34] -0.36 [-1.04, 0.32] -0.49 [-1.10, 0.12] -0.49 [-1.10, 0.12] -0.56 [-0.66, -0.26] -0.28 [-0.67, -0.11] -0.60 [-0.75, -0.44] Mean Difference	Favours [Duloxetine] Favours [placebo] Mean Difference IV, Fixed, 95% Cl -2, -1, 0, 1, 2, Favours [Duloxetine] Favours [Placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2009 Chappell 2009 Chappell 2010 Frakes 2011 Hirmanshu 2019 Murakami 2015 Uchio 2018 Wang 2017 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect: D Study or Subgroup	Z = 9.24 Dut <u>Mean</u> -1.76 -1.7 -2.4 -1.89 -1.95 -0.96 -1.72 -1.61 -1.48 8.06, df Z = 7.63 Dut <u>Mean</u>	P (P < 0 boxetin <u>SD</u> 2.14 2.74 2.23 2.38 2.09 2.36 3.04 1.42 2.07 = 8 (P c (P < 0 boxetin SD	= 0.85 0.0000 10 114 188 107 128 258 91 197 172 1426 = 0.43 0.0000 10 10 10 10 10 10 10 10 10	1) PI -0.58 -1.1 -1.64 -1.25 -0.6 -1.23 -1.05 -1.2 (; I ² = 19 I) PI Mean	acebo SD 2.17 2.82 2.06 2.38 2.08 2.33 3.07 1.48 1.62	Total 118 199 117 128 256 93 195 176 177 1459 Total	Weight 7.6% 7.4% 6.9% 18.0% 5.1% 6.3% 25.6% 15.4% 100.0% Weight	Mean Difference IV, Fixed, 95% Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.32, -0.20] -0.70 [-1.06, -0.34] -0.36 [-1.04, -0.32] -0.36 [-1.04, -0.32] -0.36 [-1.04, -0.32] -0.55 [-0.86, -0.26] -0.28 [-0.67, -0.11] -0.60 [-0.75, -0.44] Mean Difference IV, Fixed, 95% Cl	Favours [Duloxetine] Favours [placebo] Mean Difference IV, Fixed, 95% Cl -2 -1 0 1 2 Favours [Duloxetine] Favours [Placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2011 Frakes 2011 Himanshu 2019 Murakami 2015 Uchio 2018 Wang 2017 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect: D Study or Subgroup Arnold 2005	Z = 9.24 Dul <u>Mean</u> -1.76 -1.7 -2.4 -1.89 -1.95 -0.96 -1.72 -1.61 -1.48 8.06, df Z = 7.63 Dul <u>Mean</u> -2.33	P (P < 0 loxetin 2.14 2.74 2.23 2.38 2.09 2.36 3.04 1.42 2.07 = 8 (P 8 (P < 0 loxetin SD 2.46	= 0.85 0.0000 Total 114 188 107 128 258 91 191 177 172 1426 = 0.43 0.00001 114	1) PI Mean -0.58 -1.1 -1.64 -1.28 -0.6 -1.23 -1.25 () ² = 19 () PI Mean -1.15	aceboo <u>SD</u> 2.17 2.82 2.06 2.38 2.33 3.07 1.48 1.62 % aceboo <u>SD</u> 2.5	Total 118 199 117 128 256 93 195 176 177 1459 Total 118	Weight 7.6% 7.4% 6.9% 18.0% 5.1% 6.3% 25.6% 15.4% 100.0% Weight 6.8%	Mean Difference IV, Fixed, 95% Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.32, -0.20] -0.36 [-1.04, 0.32] -0.36 [-1.04, 0.32] -0.36 [-1.04, 0.32] -0.36 [-0.44, 0.32] -0.28 [-0.67, -0.44] Mean Difference IV, Fixed, 95% Cl -1.18 [-1.82, -0.54]	Favours [Duloxetine] Favours [placebo] Mean Difference IV, Fixed, 95% Cl -2, -1, 0, 1, 2, Favours [Duloxetine] Favours [Placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2010 Chappell 2010 Chappell 2010 Himanshu 2019 Hurakami 2015 Uchio 2018 Wang 2017 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect: D Study or Subgroup Arnold 2005 Arnold 2010	Z = 9.24 Dul <u>Mean</u> -1.76 -1.7 -2.4 -1.89 -1.95 -0.96 -1.72 -1.61 -1.48 8.06, df Z = 7.63 Dul <u>Mean</u> -2.33 -2.3	I (P < () loxetim SD 2.14 2.74 2.73 2.33 2.09 2.36 2.09 2.36 3.04 1.42 2.07 = = 8 (P < ()	= 0.85 0.0000 Total 114 188 107 128 258 91 191 177 172 1426 = 0.43 0.0000 16 Total 114 188 107 117 128 218 218 219 191 177 172 142 142 144 188 191 191 177 172 142 144 188 191 191 177 172 142 144 188 191 191 177 172 142 142 144 188 191 177 172 142 142 144 188 191 177 172 142 142 144 188 191 177 172 142 144 188 191 177 172 142 142 142 144 188 191 177 172 142 142 142 144 177 172 142 144 177 172 144 144 177 172 144 144 177 172 144 144 144 144 177 172 144 144 144 144 144 144 144 14	1) PI Mean -0.58 -1.1 -1.64 -1.28 -0.66 -1.23 -1.23 -1.25 -1.2 () PI Mean -1.15 -1.5	aceboo <u>SD</u> 2.17 2.82 2.06 2.38 2.08 2.33 3.07 1.48 1.62 % aceboo <u>SD</u> 2.5 2.82	Total 118 199 117 128 256 93 195 176 177 1459 Total 118 199	Weight 7.6% 7.4% 6.9% 18.0% 5.1% 6.3% 15.4% 100.0% Weight 6.8% 9.0%	Mean Difference IV, Fixed, 95%, Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.6, -0.34] -0.36 [-1.04, -0.32] -0.49 [-1.10, -0.12] -0.55 [-0.86, -0.26] -0.28 [-0.67, -0.11] -0.60 [-0.75, -0.44] Mean Difference IV, Fixed, 95%, Cl -1.18 [-1.82, -0.54]	Favours [Duloxetine] Favours [placebo] Mean Difference IV, Fixed, 95% Cl -2, -1, 0, 1, 2, Favours [Duloxetine] Favours [Placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2009 Chappell 2009 Chappell 2019 Murakami 2015 Murakami 2015 Uchio 2018 Wang 2017 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect: D Study or Subgroup Arnold 2005 Arnold 2005 Arnold 2005	Z = 9.24 Dul <u>Mean</u> -1.76 -1.7 -2.4 -1.89 -1.95 -0.96 -1.72 -1.61 -1.48 8.06, df Z = 7.63 Dul <u>Mean</u> -2.33 -2.33 -3.17	$\begin{array}{c} (P < 0 \\ \text{location} \\ \hline \text{SD} \\ 2.74 \\ 2.23 \\ 2.38 \\ 2.09 \\ 2.36 \\ 3.04 \\ 1.42 \\ 2.07 \\ \hline \text{e} \ 8 \ (P < 0 \\ \text{location} \\ \hline \text{sD} \\ 2.46 \\ 2.74 \\ 2.38 \end{array}$	= 0.85(5) 0.0000 re <u>Total</u> 114 188 107 128 258 91 191 177 172 1426 = 0.43(3) 0.0000 re <u>Total</u> 114 188 107	1) PI Mean -0.58 -1.1 -1.64 -1.25 -0.6 -1.23 -1.05 -1.2 () [² = 19 () PI Mean -1.15 -2.26	aceboo SD 2.17 2.82 2.06 2.38 2.33 3.07 1.48 1.62 % aceboo SD 2.5 2.82 2.39	Total 118 199 117 128 256 93 195 176 177 1459 Total 118 199 117	Weight 7.6% 7.4% 6.9% 18.0% 5.1% 6.3% 15.4% 100.0% Weight 6.8% 9.0% 7.1%	Mean Difference IV, Fixed, 95% Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.32, -0.20] -0.70 [-1.06, -0.34] -0.36 [-1.04, 0.32] -0.36 [-1.04, 0.32] -0.56 [-0.86, -0.26] -0.28 [-0.67, 0.11] -0.60 [-0.75, -0.44] Mean Difference IV, Fixed, 95% Cl -1.18 [-1.82, -0.54] -0.81 [-1.54, -0.28]	Favours [Duloxetine] Favours [placebo] Mean Difference IV, Fixed, 95% Cl -2, -1, 0, 1, 2, Favours [Duloxetine] Favours [Placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2011 Frakes 2011 Himanshu 2019 Murakami 2015 Uchio 2018 Wang 2017 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect: D Study or Subgroup Arnold 2010 Chappell 2009 Chappell 2011	Z = 9.24 Dui <u>Mean</u> -1.76 -1.7 -2.4 -1.89 -1.95 -0.96 -1.72 -1.61 -1.48 8.06, df Z = 7.63 Dui <u>Mean</u> -2.33 -2.3 -2.3 -2.5		= 0.85[0,0000] ne Total 114 188 107 128 258 91 177 172 1426 = 0.43] 0.0000 ne Total 114 188 107 128 191 177 128 197 191 177 128 197 197 197 197 197 197 197 197	1) PI Mean -0.58 -1.1 -1.26 -1.25 -0.6 -1.25 -2.266 -1.81	aceboo SD 2.17 2.82 2.06 2.38 2.33 3.07 1.48 1.62 % aceboo <u>SD</u> 2.55 2.82 2.39 2.26	Total 118 199 117 128 256 93 3195 176 177 1459 Total 118 199 117 128	Weight 7.6% 7.6% 7.4% 6.9% 18.0% 5.1% 6.3% 25.6% 15.4% 100.0% Weight 6.8% 9.0% 7.1% 8.6%	Mean Difference IV, Fixed, 95% Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.32, -0.20] -0.76 [-1.32, -0.20] -0.36 [-1.04, 0.32] -0.36 [-1.04, 0.32] -0.36 [-1.04, 0.32] -0.36 [-0.67, -0.12] -0.28 [-0.67, -0.14] Mean Difference IV, Fixed, 95% Cl -1.18 [-1.82, -0.54] -0.69 [-1.54, -0.28] -0.69 [-1.26, -0.12]	Favours [Duloxetine] Favours [placebo] Mean Difference IV, Fixed, 95% Cl -2, -1, 0, 1, 2, Favours [Duloxetine] Favours [Placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2009 Chappell 2009 Chappell 2019 Murakami 2015 Uchio 2018 Wang 2017 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect: D Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2010 Chappell 2011	Z = 9.24 Dui Mean -1.76 -1.7 -2.4 -1.89 -1.95 -0.96 -1.72 -1.61 -1.48 8.06, df Z Z = 7.63 Dui Mean -2.33 -2.3 -3.75 -2.51	<pre>(P < 0 (P < 0)))))))))))))))))))))))))))))))))))</pre>	= 0.85 0.0000 Total 114 188 107 128 258 91 191 191 177 172 1426 = 0.43 0.00000 Total 114 188 107 128 258 258 258 258 258 258 258 2	 Pii Mean -0.58 -1.1 -1.64 -1.25 -0.6 -1.23 -1.05 -1.05	acebo <u>SD</u> 2.17 2.82 2.06 2.33 3.07 1.48 1.62 % acebo <u>SD</u> 2.5 2.82 2.39 2.26 2.39 2.26 2.4	Total 118 199 117 128 256 93 195 176 177 1459 Total 118 199 117 128 256	Weight 7.6% 7.4% 6.9% 18.0% 5.1% 6.3% 25.6% 15.4% 100.0% Weight 6.8% 9.0% 7.1% 8.6% 16.0%	Mean Difference IV, Fixed, 95% Cl -1.18 [-1.73, -0.63] -0.00 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.04, -0.32] -0.70 [-1.06, -0.34] -0.36 [-1.04, -0.32] -0.36 [-1.04, -0.32] -0.55 [-0.86, -0.26] -0.28 [-0.67, -0.11] -0.60 [-0.75, -0.44] Mean Difference IV, Fixed, 95% Cl -1.18 [-1.82, -0.54] -0.80 [-1.35, -0.25] -0.91 [-1.54, -0.28] -0.91 [-1.54, -0.28] -0.91 [-1.54, -0.28]	Favours [Duloxetine] Favours [placebo] Mean Difference IV, Fixed, 95% Cl -2, -1, 0, 1, 2, Favours [Duloxetine] Favours [Placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2009 Chappell 2011 Hirlmanshu 2019 Murakami 2015 Uchio 2018 Wang 2017 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect: D U Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2001 Frakes 2011 Firkas 2019	Z = 9.24 Dui <u>Mean</u> -1.76 -1.77 -2.4 -1.89 -1.95 -0.96 -1.72 -1.61 -1.48 8.06, df Z = 7.63 Dui <u>Mean</u> -2.33 -2.33 -3.17 -2.51 -2.51 -1.44	$\begin{array}{c} (P < 0 \\ (P < 0 \\ SD \\ 2.14 \\ 2.74 \\ 2.23 \\ 2.36 \\ 2.36 \\ 3.04 \\ 1.42 \\ 2.07 \\ \end{array}$ $= 8 (P < 0 \\ (P < 0 \\ SD \\ 2.74 \\ 2.38 \\ 2.38 \\ 2.38 \\ 2.38 \\ 2.41 \\ 2.63 \\ \end{array}$	= 0.85 0.0000 ne <u>Total</u> 114 188 91 191 177 172 1426 = 0.43 0.0000 ne <u>Total</u> 114 188 107 128 258 91	() PI Mean -0.58 -1.1 -1.28 -1.25 -1.23 -1.25 -1.23 () PI Mean -1.15 -2.26 -1.81 -1.55 -2.26 -1.81 -1.55 -1.	acebo <u>SD</u> 2.17 2.82 2.06 2.33 3.07 1.48 1.62 .62 2.5 2.52 2.39 2.5 2.52 2.39 2.26 2.42 2.39 2.66 <u>SD</u> 2.47 2.52 2.32 3.07 1.48 1.62 2.52 2.52 2.33 3.07 1.48 2.52 2.52 2.52 2.52 2.52 2.52 2.52 2.52 2.52 2.55 2.52 2.55 2.52 2.52 2.55 2.52 2.52 2.55 2.52 2.52 2.55 2.52 2.55 2.52 2.55 2.52 2.55 2.52 2.55 2.52 2.52 2.55 2.52 2.55 2.52 2.52 2.52 2.55 2.52 2.55 2.52 2.54 2.55 2.54 2.55 2.54 2.55	Total 118 199 117 128 256 3 3 195 176 177 1459 Total 118 199 117 128 256 9 3	Weight 7.6% 7.6% 7.4% 6.9% 18.0% 25.6% 15.4% 100.0% Weight 6.8% 9.0% 7.1% 8.6% 16.0% 4.8%	Mean Difference IV, Fixed, 95%, Cl -1.18 [-1.73, -0.63] -0.06 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.61 [-1.19, -0.03] -0.36 [-1.04, -0.32] -0.36 [-1.04, -0.32] -0.56 [-0.86, -0.26] -0.28 [-0.67, -0.11] -0.60 [-0.75, -0.44] Mean Difference IV, Fixed, 95%, Cl -1.18 [-1.82, -0.54] -0.91 [-1.54, -0.28] -0.91 [-1.44, -0.28] -0.92 [-1.26, -0.12] -0.71 [-1.13, -0.29] -0.27 [-1.03, 0.49]	Favours [Duloxetine] Favours [placebo] Mean Difference IV, Fixed, 95% Cl -2, -1, 0, 1, 2, Favours [Duloxetine] Favours [Placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2010 Chappell 2010 Chappell 2010 Himanshu 2019 Murakami 2015 Uchio 2018 Wang 2017 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect: D Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2001 Frakes 2011 Frakes 2011 Frakes 2011 Himanshu 2019	Z = 9.24 Dui <u>Mean</u> -1.76 -1.77 -2.4 -1.89 -0.96 -1.72 -1.61 -1.48 8.06, df Z = 7.63 Dui <u>Mean</u> -2.33 -2.3 -3.17 -2.5 -2.51 -1.44 -1.77	$\downarrow (P < 0$ $\frac{SD}{2.14}$ $\frac{SD}{2.36}$ $\frac{2.38}{3.04}$ $\frac{2.36}{1.42}$ $\frac{2.09}{2.36}$ $\frac{2.36}{3.04}$ $\frac{1.42}{2.07}$ $= 8 (P < 0$ $\frac{SD}{2.46}$ $\frac{2.46}{2.38}$ $\frac{2.44}{2.38}$ $\frac{2.41}{2.38}$ $\frac{2.41}{2.$	= 0.85 0.0000 ne <u>Total</u> 114 188 107 128 258 91 191 177 1426 = 0.43 0.00007 ne <u>Total</u> 114 188 107 128 258 91 191 172 1426 = 0.43 0.0000 ne <u>Total</u> 114 188 107 128 258 91 191 172 1426 = 0.43 0.0000 ne <u>Total</u> 191 172 1426 = 0.43 0.0000 <u>172</u> 1426 = 0.43 0.0000 <u>172</u> 1426 = 0.43 0.0000 <u>172</u> 1426 <u>172</u> 1426 <u>172</u> 1426 <u>172</u> 1426 <u>172</u> 1426 <u>172</u> 1426 <u>172</u> 1426 <u>172</u> 1426 <u>172</u> <u>172</u> <u>172</u> <u>172</u> <u>172</u> <u>172</u> <u>172</u> <u>172</u> <u>172</u> <u>172</u> <u>172</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1745</u> <u>1742</u> <u>1742</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>17</u>	 PI Mean -0.58 -1.1 -1.64 -1.28 -1.26 -1.23 -1.25 -1.25 -1.25 -1.21 -1.15 -1.55 -1.25 -1.21 -1.15 -2.26 -1.81 -1.71 -1.27 -1.27 	aceboo 5D 2.17 2.82 2.06 2.33 3.07 1.48 1.62 % aceboo 5D 2.55 2.52 2.39 2.26 2.44 2.63 3.63	Total 118 199 117 128 256 93 195 176 177 1459 Total 118 199 191 128 256 93 195	Weight 7.6% 7.4% 6.9% 18.0% 5.1% 6.3% 15.4% 100.0% Weight 6.8% 9.0% 7.1% 8.6% 16.0% 4.8% 5.3%	Mean Difference IV, Fixed, 95%, Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.6, -0.34] -0.36 [-1.04, -0.32] -0.49 [-1.10, -0.12] -0.55 [-0.86, -0.26] -0.28 [-0.67, -0.11] -0.60 [-0.75, -0.44] Mean Difference IV, Fixed, 95%, Cl -1.18 [-1.82, -0.54] -0.80 [-1.35, -0.25] -0.91 [-1.54, -0.28] -0.69 [-1.26, -0.12] -0.71 [-1.13, -0.29] -0.57 [-1.29, 0.15]	Favours [Duloxetine] Favours [placebo] Mean Difference IV, Fixed, 95% Cl -2, -1, 0, 1, 2, Favours [Duloxetine] Favours [Placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2009 Chappell 2009 Chappell 2009 Chappell 2010 Uchio 2018 Wang 2017 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect: D Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2010 Chappell 2010 Chappell 2011 Himanshu 2019 Murakami 2015 Uchio 2018	Z = 9.24 Dui <u>Mean</u> -1.76 -1.7 -2.4 -1.85 -0.96 -1.72 -1.95 -0.96 -1.72 -1.48 8.06, df f Z = 7.62 Dui <u>Mean</u> -2.3 -3.17 -2.51 -1.44 -1.77 -2.29	$\begin{array}{c} (P < 0 \\ (P < $	= 0.85 0.0000 ne <u>Total</u> 114 188 107 128 258 91 191 177 172 1426 = 0.43 0.0000 <u>Total</u> 188 107 172 1426 = 0.43 0.0000 <u>Total</u> 144 188 107 128 258 91 114 114 188 107 128 107 128 107 128 107 128 107 128 107 128 107 128 107 128 107 128 107 128 107 128 107 128 107 128 107 128 107 128 107 128 107 128 107 128 107 107 172 1426 107 107 172 1426 107 107 172 1426 1428 107 114 107 128 107 172 1428 107 109 114 107 128 107 1172 1142 1142 1144 114 1148 1144 1148 1144 1148 1144 1148 114 114	() PI Mean -0.58 -1.1 -1.28 -1.25 -1.23 -1.25 -1.23 -1.25 -1.15 -2.26 -1.15 -1.15 -1.15 -1.28 -1.15 -1.15 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.25 -1.25 -1.21 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.26 -1.23 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.55 -1.55 -1.55 -1.55 -1.28 -1.55 -1.55 -1.28 -1.55 -1.28 -1.55 -1.55 -1.28 -1.55 -1.55 -1.28 -1.55 -1.28 -1.55 -1.28 -1.55 -1.28 -1.55 -1.28 -1.55 -1.28 -1.55 -1.28 -1.55 -1.28 -1.55 -1.28 -1.55 -1.28 -1.55 -1.25 -1.55 -1.	acebo <u>SD</u> 2.17 2.82 2.06 2.38 2.38 2.38 1.48 1.62 % acebo <u>SD</u> 2.5 2.82 2.26 <u>2.4</u> 2.66 3.63 1.75	Total 118 199 117 128 256 93 195 176 177 1459 1459 1459 117 128 256 93 195 128 256 93 195 176	Weight 7.6% 7.4% 6.9% 18.0% 5.1% 6.3% 25.6% 15.4% 100.0% Weight 6.8% 9.0% 7.1% 8.6% 16.0% 4.8% 5.3% 21.5%	Mean Difference IV, Fixed, 95% Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.32, -0.20] -0.76 [-1.04, -0.32] -0.36 [-1.04, -0.32] -0.36 [-1.04, -0.32] -0.36 [-1.04, -0.32] -0.55 [-0.86, -0.26] -0.28 [-0.67, -0.11] -0.60 [-0.75, -0.44] Mean Difference IV, Fixed, 95% Cl -1.18 [-1.82, -0.54] -0.80 [-1.54, -0.28] -0.80 [-1.54, -0.28] -0.91 [-1.54, -0.28] -0.77 [-1.13, -0.41]	Favours [Duloxetine] Favours [placebo] Mean Difference IV, Fixed, 95% Cl -2, -1, 0, 1, 2, Favours [Duloxetine] Favours [Placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2010 Chappell 2010 Chappell 2010 Himanshu 2019 Murakami 2015 Uchio 2018 Wang 2017 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect: D Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2001 Frakes 2011 Frakes 2011 Frakes 2011 Himanshu 2019	Z = 9.24 Dui <u>Mean</u> -1.76 -1.7 -2.4 -1.85 -0.96 -1.72 -1.95 -0.96 -1.72 -1.48 8.06, df f Z = 7.62 Dui <u>Mean</u> -2.3 -3.17 -2.51 -1.44 -1.77 -2.29	$\downarrow (P < 0$ $\frac{SD}{2.14}$ $\frac{SD}{2.36}$ $\frac{2.38}{3.04}$ $\frac{2.36}{1.42}$ $\frac{2.09}{2.36}$ $\frac{2.36}{3.04}$ $\frac{1.42}{2.07}$ $= 8 (P < 0$ $\frac{SD}{2.46}$ $\frac{2.46}{2.38}$ $\frac{2.44}{2.38}$ $\frac{2.41}{2.38}$ $\frac{2.41}{2.$	= 0.85 0.0000 ne <u>Total</u> 114 188 107 128 258 91 191 177 1426 = 0.43 0.00007 ne <u>Total</u> 114 188 107 128 258 91 191 172 1426 = 0.43 0.0000 ne <u>Total</u> 114 188 107 128 258 91 191 172 1426 = 0.43 0.0000 ne <u>Total</u> 191 172 1426 = 0.43 0.0000 <u>172</u> 1426 = 0.43 0.0000 <u>172</u> 1426 = 0.43 0.0000 <u>172</u> 1426 <u>172</u> 1426 <u>172</u> 1426 <u>172</u> 1426 <u>172</u> 1426 <u>172</u> 1426 <u>172</u> 1426 <u>172</u> 1426 <u>172</u> <u>172</u> <u>172</u> <u>172</u> <u>172</u> <u>172</u> <u>172</u> <u>172</u> <u>172</u> <u>172</u> <u>172</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1742</u> <u>1745</u> <u>1742</u> <u>1742</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>1745</u> <u>17</u>	 PI Mean -0.58 -1.1 -1.64 -1.28 -1.26 -1.23 -1.25 -1.25 -1.25 -1.21 -1.15 -1.55 -1.25 -1.21 -1.15 -2.26 -1.81 -1.71 -1.27 -1.27 	acebo <u>SD</u> 2.17 2.82 2.06 2.38 2.38 2.38 1.48 1.62 % acebo <u>SD</u> 2.5 2.82 2.26 <u>2.4</u> 2.66 3.63 1.75	Total 118 199 117 128 256 93 195 176 177 1459 Total 118 199 191 128 256 93 195	Weight 7.6% 7.4% 6.9% 18.0% 5.1% 6.3% 15.4% 100.0% Weight 6.8% 9.0% 7.1% 8.6% 16.0% 4.8% 5.3%	Mean Difference IV, Fixed, 95%, Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.6, -0.34] -0.36 [-1.04, -0.32] -0.49 [-1.10, -0.12] -0.55 [-0.86, -0.26] -0.28 [-0.67, -0.11] -0.60 [-0.75, -0.44] Mean Difference IV, Fixed, 95%, Cl -1.18 [-1.82, -0.54] -0.80 [-1.35, -0.25] -0.91 [-1.54, -0.28] -0.69 [-1.26, -0.12] -0.71 [-1.13, -0.29] -0.57 [-1.29, 0.15]	Favours [Duloxetine] Favours [placebo] Mean Difference IV, Fixed, 95% Cl -2, -1, 0, 1, 2, Favours [Duloxetine] Favours [Placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2009 Chappell 2009 Chappell 2009 Chappell 2017 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect: D Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2010 Chappell 2010 Chappell 2010 Chappell 2011 Friakes 2011 Hirmanshu 2019 Murakami 2015 Uchio 2018 Warakami 2015	Z = 9.24 Dui <u>Mean</u> -1.76 -1.7 -2.4 -1.85 -0.96 -1.72 -1.95 -0.96 -1.72 -1.48 8.06, df f Z = 7.62 Dui <u>Mean</u> -2.3 -3.17 -2.51 -1.44 -1.77 -2.29	$\begin{array}{c} (P < 0 \\ (P < $	= 0.85 0.0000 Total 114 188 107 128 258 91 191 177 172 1426 = 0.43 0.0000 177 172 1426 177 172 1426 177 172 1426 114 188 91 191 177 172 1426 114 188 91 191 177 172 1426 114 177 172 1426 114 177 172 1426 114 117 177 172 1426 117 177 172 1426 117 177 172 1426 117 177 177 177 177 177 177 17	() PI Mean -0.58 -1.1 -1.28 -1.25 -1.23 -1.25 -1.23 -1.25 -1.15 -2.26 -1.15 -1.15 -1.15 -1.28 -1.15 -1.15 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.28 -1.21 -1.25 -1.25 -1.21 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.26 -1.23 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.25 -1.55 -1.55 -1.55 -1.55 -1.28 -1.55 -1.55 -1.28 -1.55 -1.28 -1.55 -1.55 -1.28 -1.55 -1.55 -1.28 -1.55 -1.28 -1.55 -1.28 -1.55 -1.28 -1.55 -1.28 -1.55 -1.28 -1.55 -1.28 -1.55 -1.28 -1.55 -1.28 -1.55 -1.28 -1.55 -1.25 -1.55 -1.	acebo <u>SD</u> 2.17 2.82 2.06 2.38 2.38 2.38 1.48 1.62 % acebo <u>SD</u> 2.5 2.82 2.26 <u>2.4</u> 2.66 3.63 1.75	Total 118 199 117 128 256 93 195 176 177 1459 117 1459 117 128 256 93 195 128 256 93 195 176 177	Weight 7.6% 7.6% 18.0% 5.1% 6.3% 15.4% 100.0% Weight 16.0% 8.6% 8.6% 8.8% 8.8% 21.5% 20.9%	Mean Difference IV, Fixed, 95% Cl -1.18 [-1.73, -0.63] -0.00 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.32, -0.20] -0.70 [-1.06, -0.34] -0.36 [-1.04, 0.32] -0.36 [-1.04, 0.32] -0.55 [-0.86, -0.26] -0.28 [-0.67, -0.11] -0.60 [-0.75, -0.44] Mean Difference IV, Fixed, 95% Cl -1.18 [-1.82, -0.54] -0.80 [-1.35, -0.25] -0.91 [-1.54, -0.28] -0.91 [-1.54, -0.28] -0.91 [-1.54, -0.29] -0.77 [-1.13, -0.41] -0.77 [-1.13, -0.41] -0.47 [-0.83, -0.11]	Favours [Duloxetine] Favours [placebo] Mean Difference IV, Fixed, 95% Cl -2, -1, 0, 1, 2, Favours [Duloxetine] Favours [Placebo] Mean Difference
Heterogeneity: Chi ² = Test for overall effect: C Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2009 Chappell 2009 Chappell 2009 Chappell 2010 Uchio 2018 Wang 2017 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect: D Study or Subgroup Arnold 2005 Arnold 2010 Chappell 2010 Chappell 2010 Chappell 2011 Himanshu 2019 Murakami 2015 Uchio 2018	Z = 9.24 Mean -1.76 -1.7 -2.4 -1.89 -1.95 -1.95 -1.95 -1.72 -1.61 -1.48 8.06, df Z = 7, 63 Dulu Mean -2.33 -3.17 -2.51 -1.44 -1.74 -2.29 -2.21	$\begin{array}{c} (P < 0 \\ (P < 0 \\ space{-1}) \\ (P < 0$	= 0.85 0.0000 Total 114 188 107 128 91 191 177 172 1426 = 0.43 0.0000 re Total 114 188 107 177 172 1426 = 0.43 191 114 114 188 107 177 172 1426 = 0.43 191 114 114 118 107 177 172 1426 117 177 172 1426 117 177 177 177 177 177 177 17	() PI Mean. -0.58 -1.1 -1.64 -1.25 -0.6 -1.23 -1.25 -1.2 -1.2 (; ² = 19)) PI Mean. -1.5 -2.26 -1.81 -1.81 -1.7 -1.25 -1.25 -1.25 -2.26 -1.81 -1.11 -1.52 -1.74	aceboo SD 2.17 2.82 2.06 2.38 2.33 3.07 1.48 1.62 2.5 2.82 2.5 2.82 2.26 2.4 2.6 2.4 2.6 2.33 3.07 1.48 1.62 3.53 1.75 1.67	Total 118 199 117 128 256 93 195 176 177 1459 1459 1459 117 128 256 93 195 128 256 93 195 176	Weight 7.6% 7.6% 18.0% 5.1% 6.3% 15.4% 100.0% Weight 16.0% 8.6% 8.6% 8.8% 8.8% 21.5% 20.9%	Mean Difference IV, Fixed, 95% Cl -1.18 [-1.73, -0.63] -0.60 [-1.15, -0.05] -0.76 [-1.32, -0.20] -0.76 [-1.32, -0.20] -0.76 [-1.04, -0.32] -0.36 [-1.04, -0.32] -0.36 [-1.04, -0.32] -0.36 [-1.04, -0.32] -0.55 [-0.86, -0.26] -0.28 [-0.67, -0.11] -0.60 [-0.75, -0.44] Mean Difference IV, Fixed, 95% Cl -1.18 [-1.82, -0.54] -0.80 [-1.54, -0.28] -0.80 [-1.54, -0.28] -0.91 [-1.54, -0.28] -0.77 [-1.13, -0.41]	Favours [Duloxetine] Favours [placebo] Mean Difference IV, Fixed, 95% Cl -2, -1, 0, 1, 2, Favours [Duloxetine] Favours [Placebo] Mean Difference

Fig. 3 Forest plot: Effects of duloxetine on pain measured by BPI – S: (A) average pain; (B) worst pain; (C) least pain; (D) pain right now. The black horizontal lines represent the 95% confidence intervals, while the squares represent the point estimate. The black diamond represents the overall point estimate and 95% confidence intervals

Effects of duloxetine on the physical function

Six trials were included in the mate-analysis of WOMAC subscale, and these studies showed that duloxetine can significantly improve the total score of limb function (4 articles; 1479 patients; MD= -5.43; 95% CI, -6.87 to -3.99; P<0.00001) (Fig. 5A), pain (4 articles; 1457 patients; MD= -1.63; 95% CI, -2.63 to -0.63; P=0.001) (Fig. 5B), stiffness (6 articles; 2002 patients; MD= -0.48; 95% CI, -0.77 to -0.19; P=0.001) (Fig. 5C), physical function (6 articles; 1996 patients; MD= -4.53; 95% CI, -5.83 to -3.22; P<0.00001) (Fig. 5D) than placebo control. These evidences showed that duloxetine can improve the physical function for the patients with CMP.

Effects of duloxetine in patient's global impression

This meta-analysis revealed that duloxetine had improvement of patient's global impression significantly than placebo control measured by CGI-S (12 articles; 3601 patients; MD= -0.35; 95% CI, -0.41 to -0.28; P<0.00001) (Fig. 6A) and PGI-I (10 articles; 3099 patients; MD= -0.48; 95% CI, -0.58 to -0.39; P<0.00001) (Fig. 6B).

Safety

Ten trials described the number of serious adverse reactions. The results of this meta-analysis showed that there was no significant difference in the rate of SAEs between duloxetine and placebo groups (10 trials; 3409 patients; RR=0.81; 95% CI, 0.43 to 1.53; P=0.52) (Fig. 7).




Fig. 4 Forest plot: Effects of duloxetine in the interference of pain and quality of life measured by BPI-I: (A)general activity; (B)mood; (C) walking ability; (D) normal work; (E) relations with other people; (F) sleep; (G) enjoyment of life; (H) average interference. The black horizontal lines represent the 95% confidence intervals, while the squares represent the point estimate. The black diamond represents the overall point estimate and 95% confidence intervals




Fig. 5 Forest plot: Effects of duloxetine on the physical function measured by WOMAC: (A)total subscale;(B) pain subscale; (C) stiffness subscale;(D) physical function subscale. The black horizontal lines represent the 95% confidence intervals, while the squares represent the point estimate. The black diamond represents the overall point estimate and 95% confidence intervals

Sensitivity analysis

To validate the reliability of results, each of the 13 studies was sequentially eliminated one by one, and sensitivity analysis of the remaining studies was conducted at each step. The sensitivity analysis showed that no individual study significantly influenced the results, indicating the robust result of this meta-analysis. Sensitivity analysis images can be found in the Additional file 3.

Publication bias

We used funnel plot and Egger's test to detect publication bias in the outcome of the BPI-S 24 h average pain. No distinct asymmetry could be observed from the shape of funnel plot, suggesting no proof of publication bias (p=0.492) (Fig. 8).

Discussion

Consistent with previous studies, the results of this metaanalysis showed that duloxetine can significantly reduce the patient's pain level. It can also effectively improve patient's mood and quality of life, which may be related to its pain relief effect, and delay the progress of chronic musculoskeletal diseases such as knee osteoarthritis and fibromyalgia syndrome and ameliorate the limb function of patients. Thus, duloxetine had a definite efficacy in the treatment of patients with CMP, and the incidence of SAEs was no statistically different compared with placebo control.

Today, CMP has become one of the major problems faced by the older people, which affects their normal work and life seriously. Long-term chronic pain is unfavorable to the patients' psychology and mood, and may even induce depression, anxiety, Alzheimer or other




Fig. 6 Forest plot: Effects of duloxetine in patient's global impression : (A)CGI-S; (B)PGI-I. The black horizontal lines represent the 95% confidence intervals, while the squares represent the point estimate. The black diamond represents the overall point estimate and 95% confidence intervals

	Duloxe	Duloxetine		placebo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
Arnold 2005	1	116	0	120	2.3%	3.10 [0.13, 75.39]	
Arnold 2010	1	267	6	263	28.8%	0.16 [0.02, 1.35]	
Arnold 2012	0	155	1	153	7.2%	0.33 [0.01, 8.02]	
Chappell 2009	1	111	2	120	9.2%	0.54 [0.05, 5.88]	
Chappell 2011	3	128	2	128	9.5%	1.50 [0.25, 8.83]	
Frakes 2011	5	264	3	260	14.4%	1.64 [0.40, 6.80]	
Himanshu 2019	2	91	0	93	2.4%	5.11 [0.25, 104.97]	
Murakami 2015	1	194	1	196	4.7%	1.01 [0.06, 16.04]	
Uchio 2018	1	177	1	176	4.8%	0.99 [0.06, 15.77]	
Wang 2017	0	199	3	198	16.7%	0.14 [0.01, 2.73]	
		4700		4707	400.00/	0.04 [0.40.4 50]	
Total (95% CI)		1702		1707	100.0%	0.81 [0.43, 1.53]	
Total events	15		19				
Heterogeneity: Chi ² = 7.51, df = 9 (P = 0.58); l ² = 0%							0.001 0.1 1 10 1000
Test for overall effect: 2	Z = 0.64 (F	P = 0.52	2)				
		0.01	-,				Favours [Duloxetine] Favours [placebo]

Fig. 7 Forest plot: Effects of duloxetine in patient's safety: SAEs. The black horizontal lines represent the 95% confidence intervals, while the squares represent the point estimate. The black diamond represents the overall point estimate and 95% confidence intervals

diseases [32, 33]. Therefore, relieving pain levels is the primary goal of CMP treatment. Some researchers [34] think that chronic pain, as a high-pressure condition, is one of the critical factors for determining depression, and their coexistence tends to further aggravate the severity of both disorders and this may be the result of the fact that physical pain sensation management shares the same brain regions, neurotransmitters, and signaling pathways with emotional management which form a histological

structural foundation for the coexistence of pain and depression. The neuroplastic changes caused by chronic pain are the possible mechanisms leading to depression, which is a potentially important route for the onset and aggravation of depression. Several animal experiments and clinical studies have demonstrated that opioids can play a role in antidepressant treatment by modulating the neurotransmitter system [35, 36]. However, the serious dependence and addiction caused by opioids cannot




Fig. 8 Funnel plot: Publication bias of BPI 24-h average pain. No significant funnel asymmetry that could indicate publication bias was observed

be ignored. Therefore, the use of antidepressant drugs to exert analgesic effect has attracted more and more attention in recent years. Consistent with previous studies [37–39], this study found that duloxetine was effective in reducing patients' pain, and there was a statistical difference between the experimental group and the control group. In addition to duloxetine, a variety of antidepressant treatment [40, 41] have a positive effect on pain.

More and more studies [42-44] reported that norepinephrine and serotonin, as central descending neurotransmitters, can effectively suppress pain, and their reduction is one of the causes of anxiety and depression. The changes of norepinephrine and serotonin in the central system are thought to be the root cause of the comorbidity of pain and depression. Duloxetine, a norepinephrine and serotonin reuptake inhibitor (NSRI), can increase the levels of norepinephrine and serotonin in the central nervous system and play an antidepressant and analgesic role. This study also proved that, on the index of mood improvement, the depression symptoms of patients with CMP treated with duloxetine were significantly reduced, and they were more active in normal interpersonal communication and work life than patients with placebo control group.

The reduction of patients' pain is conducive to the improvement of patients' global impression. This study found that the evaluation of patients' global efficacy and global evaluation showed the same trend as the pain score, indicating that duloxetine has obvious efficacy for CMP and can effectively improve patients' global impression. There is a significant difference between the experimental group and the control group.

NSAIDs are currently the first-line treatment for the pain with CMP. However, Enthoven [45] demonstrated that only six of 13 RCTs included in the Cochrane review showed that NSAIDs are more effective than placebo in regard to pain improvement. Furthermore, a systematic review by Castellsague [46] also reported a higher risk of gastrointestinal complications associated with NSAIDs as compared to placebo. This systematic review found no differences in SAEs between the duloxetine and placebo groups. Meanwhile, the results are also consistent with the most recent meta-analysis [13, 47, 48]. These results demonstrate that duloxetine has the highest efficacy for reducing pain while minimizing minor adverse effects.

There are several limitations of meta-analysis that should be taken into account. First, the meta-analysis only included English literature, and based on a relatively small number of RCTs, which may lead to bias risk. Fortunately, the quality of trials we included was relatively high. Second, the included RCTs lack longterm follow-up studies, so the long-term efficacy and safety of duloxetine are still unclear. The included RCTs mostly used placebo as a control and lacked comparison with NSAIDs. Also, the current systematic review was not registered, which is a deficiency of this study. Lastly, in this study and most of the current meta-analyses, the statistical model of Meta-analysis (fixed or random effect method) is based on the results of statistical test of heterogeneity, which has certain shortcomings.

Conclusion

In conclusion, antidepressant drugs like duloxetine, is an effective treatment option for patients with CMP. Antidepressant treatment is a non-negligible factor in the treatment of CMP. This study improved that duloxetine can significantly reduce the pain level of patients, improve depressive symptoms and global impression, and has no obvious serious adverse reactions.

Any drug has two sides, and we should explore the potential issues of duloxetine in the treatment of CMP in the future. Further studies should confirm the relationship between psychological diseases and CMP, explore its internal relationship, and verify the efficacy and safety of antidepressant drugs for musculoskeletal Diseases.

Abbreviations

CMP	Chronic musculoskeletal pain
RCTs	Randomized controlled trials
SNRI	serotonin and norepinephrine reuptake inhibitor
MD	mean difference
CI	confident interval
RR	relative risk
BPI-S	Brief Pain Inventory-Severity
BPI-I	Brief Pain Inventory-Interference
WOMAC	Western Ontario and McMaster Universities Osteoarthritis Index
SF-36	36-Item Short-Form Health Status Survey
CGI-S	Clinical Global Impressions of Severity
PGI-I	Patient's Global Impression of Improvement
SAEs	serious adverse events
KOA	Knee osteoarthritis
NSAIDs	non-steroidal anti-inflammatory drugs

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12891-023-06488-6.

Supplementary	Material 1
---------------	------------

Supplementary Material 2

Supplementary Material 3

Acknowledgements

Not applicable.

Authors' contributions

All authors contributed to study design. WYS and GGL performed the searches and data collection with assistance from JS and LNW. XZM was responsible for data analysis and SJZ drafted the article. YG contributed to editing and final reviewing the article. All authors were responsible for approval of the final draft.

Funding

This work was supported by General Office of Jiangsu Provincial People's Government [2018], No.87: A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine) and Wuxi Municipal Health Commission(Q202057). The funders were not involved in any research aspects such as study design, data extraction and analysis, manuscript writing and paper submission.

Data availability

All data generated or analysed during this study are included in this published article.

Declarations

Ethics approval and consent to participate Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors report no declarations of interest

Received: 28 January 2023 / Accepted: 3 May 2023 Published online: 18 May 2023

References

- Briggs AM, Woolf AD, Dreinhöfer K, Homb N, Hoy DG, Kopansky-Giles D, Åkesson K, March L. Reducing the global burden of musculoskeletal conditions. Bull World Health Org Suppl. 2018;96(5):366–8. https://doi.org/10.2471/ blt.17.204891.
- Serawit T, Belay Y, Tesfaye Y, Mekoya T, Yimam E. Depression among Patients with Chronic Pain, in Jimma Town Public Hospitals, Ethiopia. Health Serv Res Manag Epidemiol. 2022;9:23333928221124816. https://doi. org/10.1177/2333928221124816.
- Generaal E, Vogelzangs N, Penninx BW, Dekker J, Insomnia S, Duration. Depressive symptoms, and the Onset of Chronic Multisite Musculoskeletal Pain. Sleep. 2017;40(1). https://doi.org/10.1093/sleep/zsw030.
- Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation. 2005;112(5):759–70. https://doi.org/10.1161/ circulationaha.105.568451.
- Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckerman B, Berger MF, Bao W, Lincoff AM. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016;375(26):2519–29. https://doi.org/10.1056/NEJMoa1611593.
- Brune K, Patrignani P. New insights into the use of currently available nonsteroidal anti-inflammatory drugs. J Pain Res. 2015;8:105–18. https://doi. org/10.2147/jpr.S75160.

- Aminoshariae A, Khan A. Acetaminophen: old drug, new issues. J Endod. 2015;41(5):588–93. https://doi.org/10.1016/j.joen.2015.01.024.
- Brune K, Renner B, Tiegs G. Acetaminophen/paracetamol: a history of errors, failures and false decisions. Eur J Pain. 2015;19(7):953–65. https://doi. org/10.1002/ejp.621.
- Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, Kroenke K, Bair MJ, Noorbaloochi S. Effect of Opioid vs Nonopioid Medications on Pain-Related function in patients with Chronic Back Pain or hip or knee Osteoarthritis Pain: the SPACE Randomized Clinical Trial. JAMA. 2018;319(9):872–82. https://doi.org/10.1001/jama.2018.0899.
- Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C, Barbui C. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012;10:CD006533. https://doi. org/10.1002/14651858.CD006533.pub2.
- Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions-individual patient data responder analysis. Eur J Pain. 2014;18(1):67– 75. https://doi.org/10.1002/j.1532-2149.2013.00341.x.
- Osani MC, Bannuru RR. Efficacy and safety of duloxetine in osteoarthritis: a systematic review and meta-analysis. Korean J Intern Med. 2019;34(5):966–73. https://doi.org/10.3904/kjim.2018.460.
- Hirase T, Hirase J, Ling J, Kuo PH, Hernandez GA, Giwa K, Marco R. Duloxetine for the treatment of chronic low back Pain: a systematic review of Randomized Placebo-Controlled trials. Cureus. 2021;13(5):e15169. https://doi. org/10.7759/cureus.15169.
- Higgins J, Green S, Chapter. 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0; 2011.
- 15. Ming L, Hongmei W, Maoling W. Systematic review, meta-analysis design and implementation methods. People's Medical Publishing House; 2011.
- Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327(7414):557–60. https://doi.org/10.1136/ bmj.327.7414.557.
- Xie Q, Zhang J, Lu F, Wu H, Chen Z, Jian F. Minimally invasive versus open transforaminal lumbar interbody fusion in obese patients: a meta-analysis. BMC Musculoskelet Disord. 2018;19(1):15. https://doi.org/10.1186/ s12891-018-1937-6.
- Peters JL, Sutton AJ, Jones DR et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA, 295(6), 676–80. https://doi. org/10.1001/jama.295.6.676.
- Wang G, Bi L, Li X, Li Z, Zhao D, Chen J, He D, Wang CN, Dueñas H, Skljarevski V, Yue L. Efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study. Osteoarthritis Cartilage. 2017;25(6):832–8. https://doi.org/10.1016/j. joca.2016.12.025.
- Murakami M, Osada K, Mizuno H, Ochiai T, Alev L, Nishioka K. A randomized, double-blind, placebo-controlled phase III trial of duloxetine in japanese fibromyalgia patients. Arthritis Res Ther. 2015;17:224. https://doi.org/10.1186/ s13075-015-0718-y.
- Upadhyaya HP, Arnold LM, Alaka K, Qiao M, Williams D, Mehta R. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial. Pediatr Rheumatol Online J. 2019;17(1):27. https://doi.org/10.1186/s12969-019-0325-6.
- Uchio Y, Enomoto H, Fujikoshi S, Tsuji T, Sasaki N, Tokuoka H. Efficacy of duloxetine by prior NSAID use in the treatment of chronic osteoarthritis knee pain: a post hoc subgroup analysis of a randomized, placebo-controlled, phase 3 study in Japan. J Orthop Sci. 2018;23(6):1019–26. https://doi.org/10.1016/j. jos.2018.07.008.
- Abou-Raya S, Abou-Raya A, Helmii M. Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial. Age ageing. 2012;41(5):646–52. https://doi.org/10.1093/ageing/afs072.
- Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(12):2361–72. https://doi.org/10.1185/03007 995.2011.633502.
- Chappell AS, Desaiah D, Liu-Seifert H, Zhang S, Skljarevski V, Belenkov Y, Brown JP. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract. 2011;11(1):33–41. https://doi. org/10.1111/j.1533-2500.2010.00401.x.
- 26. Chappell AS, Ossanna MJ, Liu-Seifert H, Iyengar S, Skljarevski V, Li LC, Bennett RM, Collins H. Duloxetine, a centrally acting analgesic, in the treatment of

patients with osteoarthritis knee pain: a 13-week, randomized, placebocontrolled trial. Pain. 2009;146(3):253–60. https://doi.org/10.1016/j. pain.2009.06.024.

- Russell JI, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136(3):432–44. https://doi.org/10.1016/j.pain.2008.02.024.
- Arnold LM, Zhang S, Pangallo BA. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebocontrolled study. Clin J Pain. 2012;28(9):775–81. https://doi.org/10.1097/ AJP0b013e3182510295.
- Arnold LM, Clauw D, Wang F, Ahl J, Gaynor PJ, Wohlreich MM. Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2010;37(12):2578–86. https://doi. org/10.3899/jrheum.100365.
- Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5–15. https://doi.org/10.1016/j.pain.2005.06.031.
- Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50(9):2974–84. https://doi.org/10.1002/art.20485.
- Aaron RV, Fisher EA, Palermo TM. Alexithymia in adolescents with and without chronic pain. Rehabil Psychol. 2019;64(4):469–74. https://doi.org/10.1037/ rep0000287.
- Cao S, Fisher DW, Yu T, Dong H. The link between chronic pain and Alzheimer's disease. J Neuroinflammation. 2019;16(1):204. https://doi.org/10.1186/ s12974-019-1608-z.
- Sheng J, Liu S, Wang Y, Cui R, Zhang X. The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain. Neural Plast, 2017. 2017:9724371.https://doi.org/10.1155/2017/9724371.
- Karp JF, Butters MA, Begley AE, Miller MD, Lenze EJ, Blumberger DM, Mulsant BH, Reynolds CF. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(8):e785–793. https://doi.org/10.4088/JCP.13m08725.
- Garay RP, Zarate CA, Charpeaud T, Citrome L, Correll CU, Hameg A, Llorca PM. Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother. 2017;17(6):593–609. https://doi.org/10.1080/1473 7175.2017.1283217.
- Bidari A, Moazen-Zadeh E, Ghavidel-Parsa B, Rahmani S, Hosseini S, Hassankhani A. Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial. Daru. 2019;27(1):149–58. https://doi.org/10.1007/s40199-019-00257-4.
- Gül ŞK, Tepetam H, Gül HL. Duloxetine and pregabalin in neuropathic pain of lung cancer patients. Brain Behav. 2020;10(3):e01527. https://doi.org/10.1002/ brb3.1527.

- Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359–67. https://doi.org/10.1001/jama.2013.2813.
- Bonilla-Jaime H, Sanchez-Salcedo JA, Estevez-Cabrera MM, Molina-Jimenez T, Cortes-Altamirano JL, Alfaro-Rodriguez A. Depression and Pain: Use of Antidepressants. Curr Neuropharmacol. 2022;20(2):384–402. https://doi.org/1 0.2174/1570159X19666210609161447.
- Haleem DJ. Targeting Serotonin1A receptors for treating Chronic Pain and Depression. Curr Neuropharmacol. 2019;17(12):1098–108. https://doi.org/10. 2174/1570159X17666190811161807.
- Cortes-Altamirano JL, Olmos-Hernandez A, Jaime HB, Carrillo-Mora P, Bandala C, Reyes-Long S, Alfaro-Rodríguez A. Review: 5-HT1, 5-HT2, 5-HT3 and 5-HT7 receptors and their role in the Modulation of Pain Response in the Central Nervous System. Curr Neuropharmacol. 2018;16(2):210–21. https://doi.org/10 .2174/1570159x15666170911121027.
- Attal N. Pharmacological treatments of neuropathic pain: the latest recommendations. Rev Neurol (Paris). 2019;175:46–50. https://doi.org/10.1016/j. neurol.2018.08.005.
- Pertovaara A. The noradrenergic pain regulation system: a potential target for pain therapy. Eur J Pharmacol. 2013;716:2–7. https://doi.org/10.1016/j. ejphar.2013.01.067.
- Enthoven WT, Roelofs PD, Deyo RA, van Tulder MW, Koes BW. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev. 2016;2(2CD012087. https://doi.org/10.1002/14651858.CD012087.
- 46. Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, Nicotra F, Sturkenboom M, Perez-Gutthann S. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127–46. https://doi.org/10.2165/11633470-00000000-00000.
- Rodrigues-Amorim D, Olivares JM, Spuch C, Rivera-Baltanas T. A systematic review of Efficacy, Safety, and tolerability of Duloxetine. Front Psychiatry. 2020;11:554899. https://doi.org/10.3389/fpsyt.2020.554899.
- Branton MW, Hopkins TJ, Nemec EC. Duloxetine for the reduction of opioid use in elective orthopedic surgery: a systematic review and metaanalysis. Int J Clin Pharm. 2021;43(2):394–403. https://doi.org/10.1007/ s11096-020-01216-9.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.